title: First- and second-generation drug-eluting balloons for femoro-popliteal arterial obstructions: update of technique and results.
abstract: The use of drug-eluting balloons for treatment of long-segment femoropopliteal artery obstructions has become widespread in recent years. The possibility to deliver a drug into the arterial wall with sustained antiproliferative effects, without leaving behind metal scaffolding, seems very promising. The current generation of drug-eluting balloons differs in the formulation of the drug (usually paclitaxel), technique of coating, and the elution excipients. Results of published randomized trials are reviewed in this report. A new innovative coating technique has been introduced recently. The PRIMUS® coronary drug-eluting balloon and the Legflow® peripheral drug-eluting balloon consist of paclitaxel nanoparticles that are embedded underneath the surface of the balloon as well as inside a new shellolic acid drug-release matrix. Risk for dislodgement of the paclitaxel particles is minimized in the newest generation of drug-eluting balloons. Short-term in vitro and in vivo results of this stable, coated balloon are promising, and large randomized trials have been started recently to gather more long-term and robust clinical data.
authors: Department of Vascular Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. j.vries@antoniusziekenhuis.nl
authors: J P P M
authors: JP
authors: De Vries
authors: A
authors: A
authors: Karimi
authors: B
authors: B
authors: Fioole
authors: M
authors: M
authors: Van Leersum
authors: D A B
authors: DA
authors: Werson
authors: D A F
authors: DA
authors: Van Den Heuvel
mesh_terms: D000800:Angioplasty, Balloon / Q000379:methods*; D001157:Arterial Occlusive Diseases / Q000503:physiopathology / Q000628:therapy*; D001807:Blood Vessel Prosthesis; D054855:Drug-Eluting Stents; D005263:Femoral Artery; D006801:Humans; D011150:Popliteal Artery; D011474:Prosthesis Design; D016896:Treatment Outcome; D014654:Vascular Patency